首页 | 本学科首页   官方微博 | 高级检索  
     


Peptidase activities in rats treated chronically with N(omega)-nitro-L-arginine methyl ester (L-NAME)
Authors:Linardi Alessandra  Panunto Patricia Costa  Ferro Emer Suavinho  Hyslop Stephen
Affiliation:Departamento de Farmacologia, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brazil.
Abstract:The chronic treatment of rats with N(omega)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide (NO) biosynthesis, results in hypertension. This inhibition of NO production results in activation of the renin-angiotensin system, with increased activity of the carboxypeptidase angiotensin I-converting enzyme (ACE). Since chronic NO inhibition increases ACE activity, we hypothesized that this inhibition could also affect the activities of other peptidases involved in cardiovascular functions. To test this possibility, we examined the activities of aminopeptidase M (APM), dipeptidyl peptidase IV (DPP IV), metalloendopeptidase 24.15 (MEP 24.15) and neutral endopeptidase 24.11 (NEP 24.11) in rat brain, heart, kidney, liver, lung and thoracic aorta. Male Wistar rats were treated chronically with L-NAME (80mgkg(-1) per day) administered in the drinking water for 4 weeks and their organs then removed and processed for the determination of peptidase activities. Treatment with L-NAME did not significantly alter the activities of the four peptidases in brain, heart, kidney, liver and lung. In contrast, in aorta, the activity of APM was slightly but significantly reduced whereas those of DPP IV and MEP 24.15 were markedly enhanced; NEP 24.11 was not detected in this tissue. Immunoblotting for DPP IV and MEP 24.15 showed increased expression in aortic tissue. Neither L-NAME (1-100microM) nor the NO donors sodium nitroprusside and 3-morpholinosydnonimine (SIN-1; 1-100microM) had any consistent effect on the activity of recombinant MEP 24.15 or renal DPP IV. The importance of MEP 24.15 in peptide metabolism was confirmed in pentobartibal-anesthetized rats pretreated with the MEP 24.15 inhibitor N-[1-(R,S)-carboxy-3-phenylpropyl]-Ala-Aib-Tyr-p-aminobenzoate (JA2), which significantly potentiated the hypotensive response to bradykinin. The altered peptidase activities seen in aorta may contribute to modulating vascular responses in this model of hypertension.
Keywords:ACE, angiotensin-converting enzyme   ANP, atrial natriuretic peptide   APM, aminopeptidase M   AT1, angiotensin II type 1 receptor   BNP, brain natriuretic peptide   CNP, C-type natriuretic peptide   DPP IV, dipeptidyl peptidase IV   JA2, N-[1-(R,S)-carboxy-3-phenylpropyl]-Ala-Aib-Tyr-p-aminobenzoate   MEP 24.15, metalloendopeptidase 24.15   NEP 24.11, neutral endopeptidase 24.11   L-NAME, Nω-nitro-  smallcaps"  >l-arginine methyl ester   NO, nitric oxide   NOS, nitric oxide synthase   QFS, quenched fluorescent substrate   RAS, renin-angiotensin system   SIN-1, 3-morpholinosydnonimine   SNP, sodium nitroprusside   TBS, Tris-buffered saline
本文献已被 ScienceDirect PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号